Compugen (CGEN) Corporate presentation summary

Vision and strategy

• Aims to transform patient lives by developing first-in-class therapeutics using a proprietary computational target discovery platform, Unigen™.

• Focuses on novel immuno-oncology antibodies with a rich pipeline and validating partnerships, including AstraZeneca and Gilead.

• Cash balance of $113.2M as of September 30, 2024, with an expected runway into 2027.

Pipeline and clinical programs

• Lead assets include COM701 (anti-PVRIG), COM902 (anti-TIGIT), and COM503 (anti-IL-18BP), each with unique mechanisms and clinical potential.

• COM701 is advancing into a platform trial for relapsed platinum-sensitive ovarian cancer, with study initiation in Q2 2025 and interim analysis projected for H2 2026.

• COM503, licensed to Gilead, is a first-in-class anti-IL-18BP antibody with a deal value up to $848M and ongoing Phase 1 trial.

Clinical data and efficacy

• COM701 has shown clinical benefit in multiple tumors typically unresponsive to immunotherapy, including platinum-resistant ovarian cancer, MSS colorectal cancer, and metastatic breast cancer.

• Triplet combinations of COM701 with anti-PD-1 and anti-TIGIT antibodies demonstrated consistent efficacy and durable responses in heavily pretreated ovarian cancer patients.

• COM902 monotherapy achieved a 50% disease control rate and demonstrated a favorable safety profile.